Literature DB >> 25056580

Dementia with Lewy bodies: basis of cingulate island sign.

Jonathan Graff-Radford1, Melissa E Murray1, Val J Lowe1, Bradley F Boeve1, Tanis J Ferman1, Scott A Przybelski1, Timothy G Lesnick1, Matthew L Senjem1, Jeffrey L Gunter1, Glenn E Smith1, David S Knopman1, Clifford R Jack1, Dennis W Dickson1, Ronald C Petersen1, Kejal Kantarci2.   

Abstract

OBJECTIVES: To investigate clinical, imaging, and pathologic associations of the cingulate island sign (CIS) in dementia with Lewy bodies (DLB).
METHODS: We retrospectively identified and compared patients with a clinical diagnosis of DLB (n=39); patients with Alzheimer disease (AD) matched by age, sex, and education (n=39); and cognitively normal controls (n=78) who underwent 18F-fluorodeoxyglucose (FDG) and C11 Pittsburgh compound B (PiB)-PET scans. Among these patients, we studied those who came to autopsy and underwent Braak neurofibrillary tangle (NFT) staging (n=10).
RESULTS: Patients with a clinical diagnosis of DLB had a higher ratio of posterior cingulate to precuneus plus cuneus metabolism, cingulate island sign (CIS), on FDG-PET than patients with AD (p<0.001), a finding independent of β-amyloid load on PiB-PET (p=0.56). Patients with CIS positivity on visual assessment of FDG-PET fit into the group of high- or intermediate-probability DLB pathology and received clinical diagnosis of DLB, not AD. Higher CIS ratio correlated with lower Braak NFT stage (r=-0.96; p<0.001).
CONCLUSIONS: Our study found that CIS on FDG-PET is not associated with fibrillar β-amyloid deposition but indicates lower Braak NFT stage in patients with DLB. Identifying biomarkers that measure relative contributions of underlying pathologies to dementia is critical as neurotherapeutics move toward targeted treatments.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056580      PMCID: PMC4155048          DOI: 10.1212/WNL.0000000000000734

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  Comparative evaluation of MR-based partial-volume correction schemes for PET.

Authors:  C C Meltzer; P E Kinahan; P J Greer; T E Nichols; C Comtat; M N Cantwell; M P Lin; J C Price
Journal:  J Nucl Med       Date:  1999-12       Impact factor: 10.057

2.  Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project.

Authors:  Masayuki Satoh; Hiroyasu Ishikawa; Kenichi Meguro; Masashi Kasuya; Hiroshi Ishii; Satoshi Yamaguchi
Journal:  Eur Neurol       Date:  2010-11-13       Impact factor: 1.710

3.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

4.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

5.  Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies.

Authors:  Jonathan Graff-Radford; Bradley F Boeve; Otto Pedraza; Tanis J Ferman; Scott Przybelski; Timothy G Lesnick; Prashanthi Vemuri; Matthew L Senjem; Glenn E Smith; David S Knopman; Val Lowe; Clifford R Jack; Ronald C Petersen; Kejal Kantarci
Journal:  Brain       Date:  2012-07-18       Impact factor: 13.501

6.  Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies.

Authors:  Kejal Kantarci; Chunhui Yang; Julie A Schneider; Matthew L Senjem; Denise A Reyes; Val J Lowe; Lisa L Barnes; Neelum T Aggarwal; David A Bennett; Glenn E Smith; Ronald C Petersen; Clifford R Jack; Bradley F Boeve
Journal:  Neurobiol Aging       Date:  2010-10-18       Impact factor: 4.673

7.  Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.

Authors:  Hiroshige Fujishiro; Eizo Iseki; Shinji Higashi; Koji Kasanuki; Norio Murayama; Takashi Togo; Omi Katsuse; Hirotake Uchikado; Naoya Aoki; Kenji Kosaka; Heii Arai; Kiyoshi Sato
Journal:  Neurosci Lett       Date:  2010-09-17       Impact factor: 3.046

8.  Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies.

Authors:  T J Ferman; B F Boeve; G E Smith; S-C Lin; M H Silber; O Pedraza; Z Wszolek; N R Graff-Radford; R Uitti; J Van Gerpen; W Pao; D Knopman; V S Pankratz; K Kantarci; B Boot; J E Parisi; B N Dugger; H Fujishiro; R C Petersen; D W Dickson
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

9.  Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Tanis J Ferman; Bradley F Boeve; Stephen D Weigand; Scott Przybelski; Prashanthi Vemuri; Melissa E Murray; Melissa M Murray; Matthew L Senjem; Glenn E Smith; David S Knopman; Ronald C Petersen; Clifford R Jack; Joseph E Parisi; Dennis W Dickson
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

Review 10.  Cortical circuits for the control of attention.

Authors:  Earl K Miller; Timothy J Buschman
Journal:  Curr Opin Neurobiol       Date:  2012-12-22       Impact factor: 6.627

View more
  44 in total

1.  Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.

Authors:  Jon B Toledo; Pallavi Gopal; Kevin Raible; David J Irwin; Johannes Brettschneider; Samantha Sedor; Kayla Waits; Susana Boluda; Murray Grossman; Vivianna M Van Deerlin; Edward B Lee; Steven E Arnold; John E Duda; Howard Hurtig; Virginia M-Y Lee; Charles H Adler; Thomas G Beach; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2015-12-31       Impact factor: 17.088

2.  Is dopamine transporter invariably impaired at the time of diagnosis in dementia with Lewy bodies?

Authors:  Flavio Nobili; Dario Arnaldi; Silvia Morbelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-09       Impact factor: 9.236

Review 3.  Clinical drug development for dementia with Lewy bodies: past and present.

Authors:  Garam Lee; Jeffrey Cummings; Boris Decourt; James B Leverenz; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2019-10-28       Impact factor: 6.206

4.  Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies.

Authors:  Arianna Sala; Silvia Paola Caminiti; Leonardo Iaccarino; Luca Beretta; Sandro Iannaccone; Giuseppe Magnani; Alessandro Padovani; Luigi Ferini-Strambi; Daniela Perani
Journal:  Hum Brain Mapp       Date:  2019-07-19       Impact factor: 5.038

Review 5.  Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-14       Impact factor: 5.081

Review 6.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 7.  Diagnostic Approach to Atypical Parkinsonian Syndromes.

Authors:  Nikolaus R McFarland
Journal:  Continuum (Minneap Minn)       Date:  2016-08

8.  Multimodality Imaging of Dementia: Clinical Importance and Role of Integrated Anatomic and Molecular Imaging.

Authors:  Kunal P Patel; David T Wymer; Vinay K Bhatia; Ranjan Duara; Chetan D Rajadhyaksha
Journal:  Radiographics       Date:  2020 Jan-Feb       Impact factor: 5.333

Review 9.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

Review 10.  Lewy body dementias.

Authors:  Zuzana Walker; Katherine L Possin; Bradley F Boeve; Dag Aarsland
Journal:  Lancet       Date:  2015-10-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.